Full name :
First name :
Mail :
Zip Code :
City :
Country :
Email :
Phone :
Fax :
Website :
Directory :
| Title : Modulation of arousal and sleep\/wake architecture by M(1) PAM VU0453595 across young and aged rodents and nonhuman primates - Gould_2020_Neuropsychopharmacology_45_2219 |
| Author(s) : Gould RW , Russell JK , Nedelcovych MT , Bubser M , Blobaum AL , Bridges TM , Newhouse PA , Lindsley CW , Conn PJ , Nader MA , Jones CK |
| Ref : Neuropsychopharmacology , 45 :2219 , 2020 |
| Abstract : Gould_2020_Neuropsychopharmacology_45_2219 |
| ESTHER : Gould_2020_Neuropsychopharmacology_45_2219 |
| PubMedSearch : Gould_2020_Neuropsychopharmacology_45_2219 |
| PubMedID: 32868847 |
| Title : Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound - Bertron_2016_Bioorg.Med.Chem.Lett_26_4637 |
| Author(s) : Bertron JL , Ennis EA , Tarr CJ , Wright J , Dickerson JW , Locuson CW , Blobaum AL , Rook JM , Blakely RD , Lindsley CW |
| Ref : Bioorganic & Medicinal Chemistry Lett , 26 :4637 , 2016 |
| Abstract : Bertron_2016_Bioorg.Med.Chem.Lett_26_4637 |
| ESTHER : Bertron_2016_Bioorg.Med.Chem.Lett_26_4637 |
| PubMedSearch : Bertron_2016_Bioorg.Med.Chem.Lett_26_4637 |
| PubMedID: 27575469 |
| Title : Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor - Salovich_2012_Bioorg.Med.Chem.Lett_22_5084 |
| Author(s) : Salovich JM , Vinson PN , Sheffler DJ , Lamsal A , Utley TJ , Blobaum AL , Bridges TM , Le U , Jones CK , Wood MR , Daniels JS , Conn PJ , Niswender CM , Lindsley CW , Hopkins CR |
| Ref : Bioorganic & Medicinal Chemistry Lett , 22 :5084 , 2012 |
| Abstract : Salovich_2012_Bioorg.Med.Chem.Lett_22_5084 |
| ESTHER : Salovich_2012_Bioorg.Med.Chem.Lett_22_5084 |
| PubMedSearch : Salovich_2012_Bioorg.Med.Chem.Lett_22_5084 |
| PubMedID: 22738637 |
| Title : The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease - Jones_2012_J.Pharmacol.Exp.Ther_340_404 |
| Author(s) : Jones CK , Bubser M , Thompson AD , Dickerson JW , Turle-Lorenzo N , Amalric M , Blobaum AL , Bridges TM , Morrison RD , Jadhav S , Engers DW , Italiano K , Bode J , Daniels JS , Lindsley CW , Hopkins CR , Conn PJ , Niswender CM |
| Ref : Journal of Pharmacology & Experimental Therapeutics , 340 :404 , 2012 |
| Abstract : Jones_2012_J.Pharmacol.Exp.Ther_340_404 |
| ESTHER : Jones_2012_J.Pharmacol.Exp.Ther_340_404 |
| PubMedSearch : Jones_2012_J.Pharmacol.Exp.Ther_340_404 |
| PubMedID: 22088953 |